Answers are grounded in this paper and cite their sources.
Dopamine dysregulation has long been recognized as a central feature of schizophrenia (SZ), yet the mechanisms linking genetic risk to dopaminergic dysfunction remain poorly understood. While pharmacological models have historically been used to induce hyperdopaminergic states and recapitulate select clinical features of SZ, these approaches do not model the underlying disease biology. In contrast, genetically informed models enable investigation of dopaminergic abnormalities as emergent consequences of bona fide disease-associated mechanisms. Here, we examined a mouse model of the 3q29 deletion. In humans, this 1.6 Mb deletion is typically de novo and confers a greater than 40-fold increased risk for SZ, representing the single largest known molecular risk factor for the disorder. Using this model, we identified a robust hyperdopaminergic phenotype characterized by elevated evoked dopamine release selectively within the dorsal striatum. Mechanistically, this phenotype appears to arise from a PKC-mediated reduction in dopamine transporter (DAT) availability, impairing dopamine clearance and prolonging dopaminergic signaling. Together, these results establish a direct link between a high-risk SZ mutation and striatal dopamine dysfunction, while also highlighting PKC-DAT signaling as a potential therapeutic target for treatment-resistant neuropsychiatric symptoms associated with 3q29 deletion.
No takes yet. Share an insight, caveat, or question.
Sriramoji et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: